Across TCGA pan-cancer cohorts, MIR509-2 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MIR509-2 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR509-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR509-2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and KIRP show a favorable association.
LIHC, COAD, and KIRC are the cancer types where MIR509-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.